Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge.
Responses in three chimpanzees were compared following challenge with a clonal hepatitis C virus (HCV) contained in plasma from an animal that had received infectious RNA transcripts. Two of the chimpanzees (Ch1552 and ChX0186) had recovered from a previous infection with HCV, while the third (Ch1605) was a naïve animal. All animals were challenged by reverse titration with decreasing dilutions of plasma and became serum RNA positive following challenge. Ch1605 displayed a typical disease profile for a chimpanzee. We observed increasing levels of serum RNA from week 1 postinoculation (p.i.), reaching a peak of 10(6) copies/ml at week 9 p.i., and alanine aminotransferase (ALT) elevations and seroconversion to HCV antibodies at week 10 p.i. In contrast, both Ch1552 and ChX0186 exhibited much shorter periods of viremia (4 weeks), low serum RNA levels (peak, 10(3) copies/ml), and minimal ALT elevations. A comparison of intrahepatic cytokine levels in Ch1552 and Ch1605 showed greater and earlier gamma interferon (IFN-gamma) and tumor necrosis factor alpha responses in the previously infected animal, responses that were 30-fold greater than baseline responses at week 4 p.i. for IFN-gamma in Ch1552 compared to 12-fold in Ch1605 at week 10 p.i. These data indicate (i) that clonal HCV generated from an infectious RNA transcript will lead to a typical HCV infection in naïve chimpanzees, (ii) that there are memory immune responses in recovered chimpanzees that control HCV infection upon rechallenge, and (iii) that these responses seem to be T-cell mediated, as none of the animals had detectable antibody against the HCV envelope glycoproteins. These observations have encouraging implications for the development of a vaccine for HCV.
Major
Marian E
ME
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institute of Diabetes and Digestive and Kidney Diseases/NIH, 8800 Rockville Pike, Bethesda, MD 20892, USA. major@cber.fda.ov
Mihalik
Kathleen
K
Puig
Montserrat
M
Rehermann
Barbara
B
Nascimbeni
Michelina
M
Rice
Charles M
CM
Feinstone
Stephen M
SM
D000818:Animals; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006526:Hepatitis C / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007156:Immunologic Memory; D008213:Lymphocyte Activation; D002679:Pan troglodytes; D012367:RNA, Viral / Q000097:blood; D013601:T-Lymphocytes / Q000276:immunology; D014779:Virus Replication
D016207:Cytokines; D018937:Hepatitis C Antibodies; D012367:RNA, Viral